OmniaBio
Mitchel Sivilotti has a diverse background in the biotechnology industry, with experience in various leadership roles at companies such as CCRM, Cesca Therapeutics, and TotipotentRX. Mitchel is currently the Chief Executive Officer of OmniaBio and serves as a Board Member at Standards Coordinating Body (SCB). With a Master's in Finance from Queen's University and degrees in Biology, Cellular and Molecular Biology, Mitchel has a strong educational foundation to support their successful career in the field.
This person is not in any teams
OmniaBio
OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing. OmniaBio is bringing life-saving cell and gene therapies to patients in Canada and around the world.